Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Viral Recombination

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT.

European journal of nuclear medicine and molecular imaging·2021

Same author

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.

Nature communications·2021

Same author

The Canadian Cancer Research Conference 2019.

Current oncology (Toronto, Ont.)·2020

Same author

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).

Oncoimmunology·2019

Same author

ACACIA MANGIUM: A TROPICAL FOREST TREE OF THE COASTAL LOWLANDS WITH LOW GENETIC DIVERSITY.

Evolution; international journal of organic evolution·2017

Same author

Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer.

Cancer gene therapy·2016

Search research articles

Related Experiment Video

Updated: Oct 5, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Robust envelope exchange platform for oncolytic measles virus.

S Neault¹, S Bossow², C Achard³

¹Ottawa Hospital Research Institute, Cancer Therapeutics Program, 501 Smyth Road, Ottawa, Ontario, Canada; University of Ottawa, Faculty of Medicine, 451 Smyth Rd, Ottawa, Ontario, Canada.

Journal of Virological Methods

|February 1, 2022

Summary

This study developed a platform to engineer oncolytic measles viruses (MeV) resistant to pre-existing antibodies. A chimeric MeV using canine distemper virus (CDV) envelope proteins successfully overcame immune barriers for potential cancer virotherapy.

Keywords:

Cancer Measles virus Neutralizing antibodies Oncolytic virus Pseudotyping

More Related Videos

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Oct 5, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Area of Science:

Oncolytic virotherapy
Viral immunology
Molecular virology

Background:

Oncolytic viruses (OV) offer a promising cancer treatment strategy.
Pre-existing immunity, particularly neutralizing antibodies against measles virus (MeV), hinders OV efficacy.
Antibodies target MeV envelope glycoproteins (hemagglutinin and fusion proteins).

Purpose of the Study:

To engineer oncolytic MeV resistant to pre-existing anti-MeV antibodies.
To develop a versatile platform for rapid envelope exchange in MeV.
To create chimeric MeV with altered surface glycoproteins for immune evasion.

Main Methods:

Developed a novel pseudotyping platform for MeV envelope exchange.
Exchanged MeV F and H proteins with glycoproteins from vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), and canine distemper virus (CDV).
Assessed the functionality and propagation of engineered chimeric MeV.

Main Results:

Successfully generated a platform for rapid MeV envelope exchange.
Engineered MeV-VSV and MeV-NDV pseudotypes were non-functional.
An MeV-CDV pseudotype was successfully propagated to high titers, demonstrating functionality.
Highlighted the platform's pseudotyping tolerance and limitations.

Conclusions:

A robust platform for engineering immune-evasive oncolytic MeV was established.
Chimeric MeV expressing CDV envelope proteins show potential for overcoming anti-MeV immunity.
Further research is needed to optimize pseudotyping and assess therapeutic efficacy.